olmesartan medoxomil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic)	1985	144689-63-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: olmesartan medoxomil olmetec CS-866 CS866	Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Molecular weight: 558.60 Formula: C29H30N6O6 CLOGP: 3.54 LIPINSKI: 2 HAC: 12 HDO: 2 TPSA: 154.34 ALOGS: -4.88 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

olmesartan medoxomil
olmetec
CS-866
CS866

Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.

Molecular weight: 558.60
Formula: C29H30N6O6
CLOGP: 3.54
LIPINSKI: 2
HAC: 12
HDO: 2
TPSA: 154.34
ALOGS: -4.88
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.02 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	26 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
April 25, 2002	FDA	DAIICHI SANKYO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sprue-like enteropathy	551.58	11	113	30550	410	50574051
Malabsorption	379.91	11	125	30538	3581	50570880
Intestinal villi atrophy	133.19	11	29	30634	150	50574311
Hyperkalaemia	89.26	11	127	30536	47962	50526499
Dehydration	81.88	11	240	30423	152209	50422252
Colitis microscopic	75.85	11	48	30615	6472	50567989
Acute kidney injury	70.39	11	299	30364	227759	50346702
Coeliac disease	63.40	11	48	30615	8637	50565824
Renal failure	62.19	11	173	30490	106460	50468001
Systemic lupus erythematosus	56.07	11	9	30654	140613	50433848
Device related thrombosis	55.28	11	23	30640	1284	50573177
Treatment failure	54.45	11	9	30654	137628	50436833
Diarrhoea	54.24	11	569	30094	587907	49986554
Synovitis	53.97	11	6	30657	123859	50450602
Hyponatraemia	53.14	11	153	30510	95986	50478475
Blood pressure increased	51.08	11	187	30476	132945	50441516
Hypertensive crisis	47.99	11	49	30614	13105	50561356
Drug ineffective	47.01	11	298	30365	819035	49755426
Wound	46.41	11	5	30658	105789	50468672
Infusion related reaction	45.42	11	23	30640	169534	50404927
Off label use	44.26	11	144	30519	474282	50100179
Gallbladder polyp	42.05	11	16	30647	705	50573756
Hypertensive emergency	41.96	11	20	30643	1543	50572918
Completed suicide	41.60	11	14	30649	131875	50442586
Bradycardia	41.02	11	108	30555	64318	50510143
Therapeutic product effect decreased	40.28	11	16	30647	136034	50438427
Cerebral infarction	39.98	11	57	30606	21547	50552914
Maternal exposure during pregnancy	39.43	11	24	30639	159754	50414707
Drug intolerance	39.20	11	45	30618	219059	50355402
Renal impairment	38.55	11	117	30546	75544	50498917
Lower respiratory tract infection	38.15	11	6	30657	95195	50479266
Dizziness	36.15	11	344	30319	346025	50228436
Product use issue	36.12	11	23	30640	149452	50425009
Hypotension	35.96	11	255	30408	235214	50339247
Collagen disorder	34.81	11	10	30653	179	50574282
Contraindicated product administered	34.54	11	24	30639	148934	50425527
Oligohydramnios	33.85	11	28	30635	5722	50568739
Blood urea increased	33.44	11	55	30608	23530	50550931
Metabolic acidosis	30.99	11	71	30592	38754	50535707
Glossodynia	30.45	11	16	30647	115553	50458908
Weight decreased	30.01	11	233	30430	221012	50353449
Blood pressure decreased	29.93	11	88	30575	55821	50518640
Renal disorder	29.78	11	57	30606	27448	50547013
Pancreatic toxicity	29.23	11	6	30657	22	50574439
Toxicity to various agents	28.81	11	53	30610	212446	50362015
Arthropathy	27.62	11	33	30630	157873	50416588
Blood pressure inadequately controlled	27.19	11	22	30641	4358	50570103
Gastritis	27.08	11	61	30602	32922	50541539
Microvillous inclusion disease	26.91	11	5	30658	9	50574452
Swelling	26.43	11	51	30612	200821	50373640
Lymphocytic infiltration	26.35	11	12	30651	834	50573627
Gravitational oedema	25.58	11	13	30650	1152	50573309
Asthenia	25.34	11	300	30363	318742	50255719
Hypokalaemia	25.25	11	113	30550	87879	50486582
Cardiac failure congestive	24.70	11	109	30554	84273	50490188
Joint swelling	24.54	11	72	30591	245214	50329247
Blood creatinine increased	24.31	11	101	30562	76059	50498402
Syncope	24.30	11	125	30538	102877	50471584
Gastrooesophageal reflux disease	22.57	11	99	30564	76329	50498132
Autoimmune enteropathy	21.98	11	4	30659	6	50574455
Putamen haemorrhage	21.91	11	7	30656	182	50574279
Enteritis	21.86	11	24	30639	6971	50567490
Diverticulum	21.12	11	29	30634	10585	50563876
Spleen congestion	20.36	11	6	30657	118	50574343
Pain	19.90	11	240	30423	578663	49995798
Death	19.74	11	116	30547	325263	50249198
Condition aggravated	19.60	11	103	30560	296955	50277506
Heart rate irregular	19.60	11	39	30624	19321	50555140
Eosinophil count	19.23	11	3	30660	0	50574461
Coronary artery disease	19.08	11	50	30613	29676	50544785
Oesophagitis	18.69	11	31	30632	13352	50561109
Discomfort	18.57	11	23	30640	108357	50466104
Burn oesophageal	18.42	11	6	30657	166	50574295
Exposure during pregnancy	18.40	11	28	30635	120987	50453474
Atrial tachycardia	18.31	11	13	30650	2119	50572342
Alopecia	17.87	11	82	30581	244965	50329496
Decreased appetite	17.76	11	193	30470	200730	50373731
Large intestine polyp	17.64	11	22	30641	7310	50567151
Liver disorder	17.50	11	56	30607	37166	50537295
Prerenal failure	17.39	11	11	30652	1482	50572979
Nail disorder	17.06	11	25	30638	9683	50564778
Gastritis erosive	16.71	11	18	30645	5116	50569345
Anti-transglutaminase antibody increased	16.69	11	3	30660	4	50574457
Aortic valve calcification	16.67	11	7	30656	400	50574061
Hyperuricaemia	16.29	11	17	30646	4663	50569798
Chronic kidney disease	16.19	11	57	30606	39714	50534747
Abortion spontaneous	15.92	11	3	30660	41769	50532692
Febrile neutropenia	15.43	11	22	30641	97645	50476816
Hiatus hernia	15.14	11	34	30629	18310	50556151
Oedema peripheral	15.01	11	154	30509	157807	50416654
Azotaemia	14.74	11	15	30648	3993	50570468
Enterocolitis	14.69	11	19	30644	6548	50567913
Product administration error	14.60	11	35	30628	19664	50554797
Distributive shock	14.55	11	8	30655	832	50573629
Helicobacter infection	14.45	11	6	30657	49696	50524765
Blood glucose increased	14.41	11	83	30580	71241	50503220
Electrolyte imbalance	14.37	11	32	30631	17137	50557324
Aortic dissection	14.29	11	10	30653	1593	50572868
Hepatic enzyme abnormal	14.06	11	16	30647	4833	50569628
Hepatorenal failure	14.04	11	7	30656	596	50573865
Skin exfoliation	13.53	11	48	30615	33564	50540897
Acquired oesophageal web	13.48	11	5	30658	205	50574256
Product use in unapproved indication	13.07	11	32	30631	115787	50458674
Chronic gastritis	12.98	11	11	30652	2323	50572138
Abdominal discomfort	12.78	11	85	30578	231556	50342905
Musculoskeletal stiffness	12.62	11	38	30625	128443	50446018
Iron deficiency anaemia	12.57	11	30	30633	16804	50557657
Infection	12.52	11	58	30605	172896	50401565
Chest pain	12.15	11	162	30501	176720	50397741
Hepatitis alcoholic	12.07	11	4	30659	117	50574344
Hypovolaemia	12.00	11	21	30642	9444	50565017
Pharyngeal haematoma	11.96	11	3	30660	31	50574430
Leukopenia	11.91	11	14	30649	67514	50506947
Purpura senile	11.90	11	6	30657	523	50573938
Mucosa vesicle	11.88	11	3	30660	32	50574429
Confabulation	11.82	11	5	30658	291	50574170
Blood creatine phosphokinase increased	11.79	11	39	30624	26328	50548133
Impaired healing	11.75	11	15	30648	69771	50504690
Renal artery stenosis	11.67	11	9	30654	1663	50572798
Withdrawal hypertension	11.67	11	4	30659	130	50574331
Myocardial infarction	11.62	11	93	30570	88934	50485527
Intentional product use issue	11.50	11	18	30645	76900	50497561
General physical health deterioration	11.39	11	46	30617	142388	50432073
Feeling abnormal	11.28	11	121	30542	125371	50449090
Anaemia	11.22	11	215	30448	252241	50322220
Neutropenia	11.08	11	49	30614	147916	50426545
Bradyphrenia	11.04	11	16	30647	6136	50568325

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sprue-like enteropathy	393.16	11.79	85	20629	355	29553458
Malabsorption	339.67	11.79	102	20612	1846	29551967
Colitis microscopic	79.99	11.79	34	20680	1729	29552084
Gastrointestinal disorder	75.90	11.79	97	20617	28609	29525204
Intestinal villi atrophy	60.99	11.79	15	20699	121	29553692
Renal impairment	57.35	11.79	155	20559	81178	29472635
Coeliac disease	50.41	11.79	18	20696	570	29553243
Death	50.10	11.79	103	20611	341981	29211832
Toxicity to various agents	49.84	11.79	30	20684	173631	29380182
Blood pressure increased	42.66	11.79	131	20583	73672	29480141
Hypotension	39.65	11.79	252	20462	194102	29359711
Dehydration	36.43	11.79	168	20546	114580	29439233
Blood pressure decreased	35.42	11.79	90	20624	45387	29508426
Hepatic function abnormal	35.17	11.79	82	20632	39177	29514636
Dizziness	33.88	11.79	238	20476	189446	29364367
Diarrhoea	32.70	11.79	366	20348	332332	29221481
Off label use	31.45	11.79	107	20607	300693	29253120
Syncope	31.07	11.79	126	20588	81245	29472568
Cerebral infarction	29.55	11.79	58	20656	24617	29529196
Pulmonary hypoplasia	28.98	11.79	11	20703	415	29553398
Hyperkinetic heart syndrome	28.67	11.79	8	20706	110	29553703
Intestinal intraepithelial lymphocytes increased	28.39	11.79	5	20709	4	29553809
Interstitial lung disease	26.67	11.79	95	20619	57623	29496190
Gastrointestinal erosion	26.43	11.79	10	20704	374	29553439
Right atrial hypertrophy	26.41	11.79	11	20703	531	29553282
Hyperkalaemia	24.98	11.79	97	20617	61295	29492518
Weight decreased	24.98	11.79	186	20528	150719	29403094
Hypertensive crisis	24.74	11.79	29	20685	7819	29545994
Microvillous inclusion disease	24.44	11.79	6	20708	48	29553765
Neutropenia	24.40	11.79	34	20680	131677	29422136
Hyperuricaemia	24.33	11.79	27	20687	6862	29546951
Completed suicide	22.65	11.79	18	20696	90228	29463585
Drug abuse	22.60	11.79	14	20700	79869	29473944
Gastrooesophageal reflux disease	22.13	11.79	60	20654	31436	29522377
Transient aphasia	20.77	11.79	6	20708	94	29553719
Anaplastic astrocytoma	19.74	11.79	6	20708	113	29553700
Bronchial wall thickening	19.48	11.79	11	20703	1041	29552772
Drug ineffective	19.03	11.79	163	20551	363007	29190806
Coronary artery occlusion	19.01	11.79	29	20685	10065	29543748
Tropical sprue	18.79	11.79	3	20711	0	29553813
Bronchial secretion retention	18.54	11.79	11	20703	1142	29552671
Haemorrhoids	18.54	11.79	31	20683	11626	29542187
Right ventricular hypertrophy	18.47	11.79	11	20703	1150	29552663
Loss of consciousness	18.23	11.79	101	20613	73955	29479858
Oligohydramnios	17.47	11.79	7	20707	306	29553507
Acute kidney injury	17.27	11.79	271	20443	264996	29288817
Infective exacerbation of chronic obstructive airways disease	17.24	11.79	12	20702	1638	29552175
Product use in unapproved indication	16.50	11.79	22	20692	86853	29466960
Lymphangiectasia intestinal	16.26	11.79	3	20711	4	29553809
Aortic valve stenosis	16.23	11.79	13	20701	2195	29551618
Hypertensive emergency	16.18	11.79	9	20705	827	29552986
Hospitalisation	16.14	11.79	6	20708	45982	29507831
Hypokalaemia	15.52	11.79	73	20641	50130	29503683
Renal failure	15.19	11.79	138	20576	118461	29435352
Collagen disorder	14.86	11.79	5	20709	132	29553681
Gout	14.78	11.79	35	20679	16876	29536937
Pulmonary function test abnormal	14.75	11.79	12	20702	2070	29551743
Atrophy	14.58	11.79	9	20705	1004	29552809
Histology abnormal	14.42	11.79	6	20708	289	29553524
Intestinal ulcer perforation	13.78	11.79	3	20711	13	29553800
Febrile neutropenia	13.77	11.79	37	20677	112203	29441610
Enterocolitis viral	13.77	11.79	4	20710	64	29553749
Obstruction	13.44	11.79	11	20703	1915	29551898
Palmar-plantar erythrodysaesthesia syndrome	13.39	11.79	31	20683	14728	29539085
Echocardiogram abnormal	13.20	11.79	8	20706	863	29552950
Chronic gastritis	13.14	11.79	9	20705	1197	29552616
Rectal ulcer haemorrhage	12.94	11.79	4	20710	80	29553733
Treatment failure	12.66	11.79	5	20709	36934	29516879
Hypertension	12.62	11.79	131	20583	116483	29437330
Erosive duodenitis	12.49	11.79	9	20705	1298	29552515
Gastric cancer	12.34	11.79	16	20698	4778	29549035
Cerebral haemorrhage	12.24	11.79	49	20665	31377	29522436
Thrombocytopenia	12.06	11.79	51	20663	134772	29419041
Prerenal failure	12.03	11.79	10	20704	1778	29552035
Herpes ophthalmic	11.91	11.79	6	20708	451	29553362
Product administration error	11.84	11.79	29	20685	14281	29539532

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sprue-like enteropathy	908.61	10.54	194	41406	835	64456297
Malabsorption	545.26	10.54	174	41426	4229	64452903
Intestinal villi atrophy	184.87	10.54	44	41556	334	64456798
Colitis microscopic	147.23	10.54	79	41521	7353	64449779
Dehydration	101.55	10.54	339	41261	216424	64240708
Hyperkalaemia	101.02	10.54	210	41390	100919	64356213
Coeliac disease	94.08	10.54	59	41541	7353	64449779
Renal impairment	90.67	10.54	240	41360	134777	64322355
Diarrhoea	88.38	10.54	779	40821	721925	63735207
Gastrointestinal disorder	74.50	10.54	173	41427	89536	64367596
Toxicity to various agents	74.28	10.54	75	41525	363438	64093694
Completed suicide	69.28	10.54	29	41571	224385	64232747
Hypertensive crisis	68.41	10.54	71	41529	18177	64438955
Renal failure	67.05	10.54	263	41337	181425	64275707
Cerebral infarction	66.22	10.54	105	41495	40939	64416193
Hypotension	63.10	10.54	441	41159	380533	64076599
Off label use	62.48	10.54	205	41395	632601	63824531
Hypertensive emergency	56.03	10.54	28	41572	2248	64454884
Syncope	55.59	10.54	225	41375	157410	64299722
Acute kidney injury	55.57	10.54	486	41114	448754	64008378
Blood pressure increased	53.63	10.54	237	41363	172315	64284817
Microvillous inclusion disease	49.66	10.54	11	41589	58	64457074
Synovitis	48.87	10.54	4	41596	99086	64358046
Drug ineffective	48.78	10.54	330	41270	839917	63617215
Blood pressure decreased	48.74	10.54	144	41456	86055	64371077
Collagen disorder	48.49	10.54	14	41586	239	64456893
Weight decreased	47.97	10.54	332	41268	285407	64171725
Death	47.83	10.54	156	41444	482549	63974583
Hyperuricaemia	44.35	10.54	43	41557	10148	64446984
Device related thrombosis	43.65	10.54	23	41577	2062	64455070
Treatment failure	43.23	10.54	11	41589	116805	64340327
Hepatic function abnormal	42.80	10.54	114	41486	64199	64392933
Gastrooesophageal reflux disease	40.60	10.54	132	41468	83011	64374121
Hypokalaemia	39.82	10.54	170	41430	121733	64335399
Maternal exposure during pregnancy	37.52	10.54	8	41592	95876	64361256
Dizziness	37.47	10.54	433	41167	429730	64027402
Gallbladder polyp	37.44	10.54	16	41584	896	64456236
Enteritis	34.90	10.54	41	41559	12036	64445096
Drug intolerance	34.80	10.54	42	41558	187950	64269182
Hyponatraemia	34.77	10.54	188	41412	148151	64308981
Blood pressure inadequately controlled	33.93	10.54	28	41572	5356	64451776
Cardiac failure congestive	33.71	10.54	170	41430	130410	64326722
Renal disorder	33.60	10.54	72	41528	35293	64421839
Infusion related reaction	33.45	10.54	34	41566	164433	64292699
Bradycardia	32.72	10.54	157	41443	118062	64339070
Tropical sprue	31.74	10.54	5	41595	0	64457132
Diverticulum	30.42	10.54	40	41560	13158	64443974
Contraindicated product administered	30.07	10.54	16	41584	107813	64349319
Gastritis	29.83	10.54	77	41523	42541	64414591
Prerenal failure	29.66	10.54	21	41579	3201	64453931
Pericarditis	29.54	10.54	3	41597	62513	64394619
Therapeutic product effect decreased	29.50	10.54	19	41581	115332	64341800
Product use issue	29.03	10.54	33	41567	151682	64305450
Hyperkinetic heart syndrome	28.67	10.54	8	41592	120	64457012
Interstitial lung disease	28.66	10.54	132	41468	97600	64359532
Intestinal intraepithelial lymphocytes increased	27.36	10.54	5	41595	7	64457125
Chronic gastritis	27.27	10.54	20	41580	3220	64453912
Right atrial hypertrophy	27.23	10.54	11	41589	534	64456598
Blood urea increased	27.11	10.54	76	41524	44077	64413055
Chronic kidney disease	26.53	10.54	90	41510	57829	64399303
Lower respiratory tract infection	26.44	10.54	14	41586	94600	64362532
Drug abuse	26.20	10.54	28	41572	132346	64324786
Decreased appetite	26.19	10.54	287	41313	281002	64176130
Febrile neutropenia	26.02	10.54	51	41549	187606	64269526
Exposure during pregnancy	25.67	10.54	9	41591	77666	64379466
Systemic lupus erythematosus	25.63	10.54	9	41591	77603	64379529
Lymphocytic infiltration	25.24	10.54	14	41586	1390	64455742
Wound	25.03	10.54	9	41591	76468	64380664
Hiatus hernia	24.21	10.54	45	41555	19912	64437220
Neutropenia	23.98	10.54	77	41523	239547	64217585
Pemphigus	23.88	10.54	5	41595	60696	64396436
Large intestine polyp	23.68	10.54	32	41568	10805	64446327
Product use in unapproved indication	23.63	10.54	49	41551	176569	64280563
Pulmonary function test abnormal	23.23	10.54	18	41582	3146	64453986
Obstruction	22.81	10.54	18	41582	3230	64453902
Liver disorder	22.78	10.54	81	41519	53270	64403862
Aortic dissection	21.85	10.54	18	41582	3434	64453698
Autoimmune enteropathy	21.00	10.54	5	41595	38	64457094
Asthenia	20.97	10.54	390	41210	427654	64029478
Gravitational oedema	20.44	10.54	13	41587	1659	64455473
Arthropathy	20.35	10.54	29	41571	120938	64336194
Joint swelling	20.32	10.54	71	41529	215311	64241821
Pain	19.92	10.54	245	41355	553266	63903866
Haemorrhoids	19.59	10.54	46	41554	23955	64433177
Blood creatinine increased	19.44	10.54	152	41448	135630	64321502
Pulmonary hypoplasia	19.43	10.54	5	41595	54	64457078
Aortic valve stenosis	19.32	10.54	19	41581	4561	64452571
Exercise lack of	18.98	10.54	8	41592	433	64456699
Anaplastic astrocytoma	18.82	10.54	6	41594	145	64456987
Putamen haemorrhage	18.81	10.54	8	41592	443	64456689
Swelling	18.57	10.54	48	41552	160170	64296962
Enterocolitis	18.36	10.54	30	41570	11988	64445144
Gastrointestinal erosion	18.23	10.54	10	41590	972	64456160
Infective exacerbation of chronic obstructive airways disease	18.18	10.54	14	41586	2424	64454708
Metabolic acidosis	18.03	10.54	92	41508	70866	64386266
Transient aphasia	18.02	10.54	6	41594	167	64456965
Right ventricular hypertrophy	18	10.54	11	41589	1309	64455823
Erosive duodenitis	17.95	10.54	12	41588	1666	64455466
Condition aggravated	17.84	10.54	154	41446	372272	64084860
Cerebral haemorrhage	17.25	10.54	72	41528	51018	64406114
Gluten sensitivity	17.25	10.54	7	41593	344	64456788
Myocardial infarction	17.20	10.54	173	41427	165648	64291484
Diabetic nephropathy	17.14	10.54	14	41586	2640	64454492
Hypersensitivity	17.06	10.54	67	41533	196385	64260747
Gastric cancer	17.05	10.54	21	41579	6472	64450660
Atrial fibrillation	17.04	10.54	177	41423	170912	64286220
Hypoalbuminaemia	16.81	10.54	36	41564	17638	64439494
Nail disorder	16.66	10.54	24	41576	8600	64448532
Leukocyturia	16.46	10.54	11	41589	1527	64455605
Coronary artery occlusion	16.45	10.54	31	41569	13860	64443272
Gout	16.36	10.54	40	41560	21373	64435759
Hypertension	16.26	10.54	246	41354	259015	64198117
Heart rate irregular	15.67	10.54	46	41554	27367	64429765
Chest pain	15.61	10.54	226	41374	235754	64221378
Rheumatoid arthritis	15.60	10.54	54	41546	164240	64292892
Infection	15.45	10.54	64	41536	184816	64272316
Lymphangiectasia intestinal	15.43	10.54	3	41597	7	64457125
Renal cyst haemorrhage	15.40	10.54	7	41593	455	64456677
Ileal ulcer	15.30	10.54	9	41591	999	64456133
Bradyphrenia	15.08	10.54	24	41576	9382	64447750
Rhabdomyolysis	15.00	10.54	106	41494	91620	64365512
Musculoskeletal stiffness	14.98	10.54	36	41564	123170	64333962
Anti-transglutaminase antibody increased	14.89	10.54	3	41597	9	64457123
Glossodynia	14.78	10.54	12	41588	64684	64392448
Hospitalisation	14.77	10.54	16	41584	75191	64381941
Presyncope	14.74	10.54	53	41547	35036	64422096
Gastritis erosive	14.72	10.54	24	41576	9571	64447561
Encephalopathy	14.61	10.54	10	41590	58809	64398323
Histology abnormal	14.55	10.54	6	41594	307	64456825
Bronchial wall thickening	14.33	10.54	11	41589	1896	64455236
Skin exfoliation	14.18	10.54	62	41538	44823	64412309
Intentional product use issue	14.02	10.54	25	41575	95339	64361793
Autoimmune hepatitis	13.84	10.54	24	41576	10060	64447072
Bradykinesia	13.77	10.54	19	41581	6541	64450591
Iron deficiency anaemia	13.75	10.54	38	41562	21851	64435281
Coronary artery disease	13.74	10.54	76	41524	60357	64396775
Polyp	13.52	10.54	19	41581	6654	64450478
General physical health deterioration	13.47	10.54	77	41523	204348	64252784
Hypocalcaemia	13.44	10.54	58	41542	41695	64415437
Blood potassium increased	13.36	10.54	42	41558	25938	64431194
Lymphocytosis	13.34	10.54	14	41586	3630	64453502
Intestinal ulcer perforation	13.22	10.54	3	41597	18	64457114
Hypomagnesaemia	12.87	10.54	53	41547	37323	64419809
Leukopenia	12.78	10.54	29	41571	101213	64355919
Anaemia	12.75	10.54	327	41273	378353	64078779
Aortic valve calcification	12.73	10.54	7	41593	683	64456449
Oedema peripheral	12.20	10.54	197	41403	210120	64247012
Atrophy	12.19	10.54	10	41590	1897	64455235
Normochromic normocytic anaemia	12.03	10.54	18	41582	6672	64450460
Gastrointestinal hypermotility	12.00	10.54	5	41595	263	64456869
Generalised oedema	11.93	10.54	35	41565	20818	64436314
Duodenitis	11.92	10.54	18	41582	6723	64450409
Hypovolaemia	11.90	10.54	29	41571	15457	64441675
Disease progression	11.86	10.54	49	41551	141631	64315501
Atrial tachycardia	11.84	10.54	13	41587	3546	64453586
Loss of consciousness	11.83	10.54	147	41453	148218	64308914
Drug resistance	11.71	10.54	4	41596	35098	64422034
Mucosa vesicle	11.69	10.54	3	41597	32	64457100
Bronchial secretion retention	11.63	10.54	11	41589	2516	64454616
Disturbance in attention	11.59	10.54	6	41594	41068	64416064
Acquired oesophageal web	11.57	10.54	5	41595	288	64456844
Diabetes mellitus inadequate control	11.45	10.54	35	41565	21286	64435846
Thalamus haemorrhage	11.43	10.54	9	41591	1610	64455522
Duodenal ulcer haemorrhage	11.35	10.54	17	41583	6308	64450824
Hepatitis acute	11.30	10.54	26	41574	13363	64443769
Hypoglycaemia	10.92	10.54	97	41503	89795	64367337
Paranasal sinus haematoma	10.88	10.54	3	41597	43	64457089
Peripheral swelling	10.67	10.54	85	41515	209068	64248064
Diverticulum intestinal	10.63	10.54	18	41582	7402	64449730
Embolic stroke	10.59	10.54	17	41583	6694	64450438

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09CA08	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain
ATC	C09DA08	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics
ATC	C09DB02	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC	C09DX03	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA	N0000000070	Angiotensin 2 Receptor Antagonists
FDA EPC	N0000175561	Angiotensin 2 Receptor Blocker
MeSH PA	D047228	Angiotensin II Type 1 Receptor Blockers
MeSH PA	D057911	Angiotensin Receptor Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:61016	angiotensin receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	off-label use	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diastolic heart failure	off-label use	418304008	DOID:9775
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Angioedema	contraindication	41291007	DOID:1558
Hypokalemia	contraindication	43339004
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Low blood pressure	contraindication	45007003
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Hepatic failure	contraindication	59927004
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic idiopathic constipation	contraindication	82934008
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Azotemia	contraindication	445009001
Severe Aortic Valve Stenosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.25	acidic
pKa2	5.76	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Type-1 angiotensin II receptor	GPCR	P30556	AGTR1_HUMAN	ANTAGONIST	IC50	8.10		IUPHAR	CHEMBL
Type-1 angiotensin II receptor	GPCR		AGTR1_BOVIN		IC50	8.09		CHEMBL

External reference:

ID	Source
4021345	VUID
N0000179505	NUI
D01204	KEGG_DRUG
4021344	VANDF
4021345	VANDF
C0386393	UMLSCUI
CHEBI:31932	CHEBI
CHEBI:48416	CHEBI
OLM	PDB_CHEM_ID
CHEMBL1200692	ChEMBL_ID
D000068557	MESH_DESCRIPTOR_UI
C437965	MESH_SUPPLEMENTAL_RECORD_UI
591	IUPHAR_LIGAND_ID
7787	INN_ID
144689-24-7	SECONDARY_CAS_RN
6M97XTV3HD	UNII
130881	PUBCHEM_CID
158781	PUBCHEM_CID
DB00275	DRUGBANK_ID
118463	RXNORM
16642	MMSL
245076	MMSL
d04801	MMSL
009634	NDDF
009635	NDDF
385540001	SNOMEDCT_US
412259001	SNOMEDCT_US
412260006	SNOMEDCT_US
C1098320	UMLSCUI
CHEMBL1516	ChEMBL_ID
8612	INN_ID
8W1IQP3U10	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5002	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5003	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5004	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5005	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5006	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2425	TABLET, FILM COATED	5 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2425	TABLET, FILM COATED	5 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2426	TABLET, FILM COATED	20 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2426	TABLET, FILM COATED	20 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2427	TABLET, FILM COATED	40 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2427	TABLET, FILM COATED	40 mg	ORAL	ANDA	31 sections
Azor	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0870	TABLET, FILM COATED	20 mg	ORAL	NDA	26 sections
Azor	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0871	TABLET, FILM COATED	20 mg	ORAL	NDA	26 sections
Azor	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0872	TABLET, FILM COATED	40 mg	ORAL	NDA	26 sections
Azor	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0873	TABLET, FILM COATED	40 mg	ORAL	NDA	26 sections
Tribenzor	HUMAN PRESCRIPTION DRUG LABEL	3	0713-0874	TABLET, FILM COATED	20 mg	ORAL	NDA	28 sections
Tribenzor	HUMAN PRESCRIPTION DRUG LABEL	3	0713-0875	TABLET, FILM COATED	40 mg	ORAL	NDA	28 sections
Tribenzor	HUMAN PRESCRIPTION DRUG LABEL	3	0713-0876	TABLET, FILM COATED	40 mg	ORAL	NDA	28 sections
Tribenzor	HUMAN PRESCRIPTION DRUG LABEL	3	0713-0877	TABLET, FILM COATED	40 mg	ORAL	NDA	28 sections
Tribenzor	HUMAN PRESCRIPTION DRUG LABEL	3	0713-0878	TABLET, FILM COATED	40 mg	ORAL	NDA	28 sections
Olmesartan Medoxomil	HUMAN PRESCRIPTION DRUG LABEL	1	13668-248	TABLET	5 mg	ORAL	ANDA	21 sections
Olmesartan Medoxomil	HUMAN PRESCRIPTION DRUG LABEL	1	13668-248	TABLET	5 mg	ORAL	ANDA	21 sections
Olmesartan Medoxomil	HUMAN PRESCRIPTION DRUG LABEL	1	13668-249	TABLET	20 mg	ORAL	ANDA	21 sections
Olmesartan Medoxomil	HUMAN PRESCRIPTION DRUG LABEL	1	13668-249	TABLET	20 mg	ORAL	ANDA	21 sections
Olmesartan Medoxomil	HUMAN PRESCRIPTION DRUG LABEL	1	13668-250	TABLET	40 mg	ORAL	ANDA	21 sections
Olmesartan Medoxomil	HUMAN PRESCRIPTION DRUG LABEL	1	13668-250	TABLET	40 mg	ORAL	ANDA	21 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE	HUMAN PRESCRIPTION DRUG LABEL	2	13668-251	TABLET	20 mg	ORAL	ANDA	20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE	HUMAN PRESCRIPTION DRUG LABEL	2	13668-251	TABLET	20 mg	ORAL	ANDA	20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE	HUMAN PRESCRIPTION DRUG LABEL	2	13668-252	TABLET	40 mg	ORAL	ANDA	20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE	HUMAN PRESCRIPTION DRUG LABEL	2	13668-252	TABLET	40 mg	ORAL	ANDA	20 sections